COVID-19
Regístrese
metricas
covid
Revista Española de Medicina Nuclear e Imagen Molecular (English Edition)
Suscribe to the journal
Buscar en
Revista Española de Medicina Nuclear e Imagen Molecular (English Edition)
Toda la web
Inicio Revista Española de Medicina Nuclear e Imagen Molecular (English Edition) Response, complications and risk of leukemic transformation of phosphorus-32p tr...
Journal Information
Back to article

Statistics

Follow this link to access the full text of the article

Original Article
Response, complications and risk of leukemic transformation of phosphorus-32p treatment in philadelphia-negative chronic myeloproliferative syndromes
Respuesta, complicaciones y riesgo de transformación leucémica del tratamiento con fósforo-32p en los síndromes mieloproliferativos crónicos philadelphia negativos.
I. Tobalina Larreaa,b,
Corresponding author
ignacio.tobalinalarrea@osakidetza.eus

Corresponding author.
, J. Cuetos Fernándezc, A. Mendizabal Abadd, A. Montero de la Peñaa, D. García Hernándeza, G.H. Portilla Quatrociocchie, M. Jiménez Alonsoe, M.C. Menchaca Echevarriad
a Servicio de Medicina Nuclear, Hospital Universitario de Álava, Osakidetza, Vitoria-Gasteiz, Álava, Spain
b Facultad de Medicina, Departamento de Cirugía, Radiología y Medicina Física, Universidad del País Vasco, UPV/EHU, Unidad Docente de Vitoria-Gasteiz, Vitoria-Gasteiz, Álava, Spain
c Servicio de Radiología, Hospital Universitario Donostia, Osakidetza, Donostia-San Sebastián, Guipúzcoa, Spain
d Servicio de Hematología y Hemoterapia, Hospital Universitario de Álava, Osakidetza, Vitoria-Gasteiz, Álava, Spain
e Servicio de Medicina Nuclear, Hospital Universitario de Cruces, Osakidetza, Baracaldo-Cruces, Vizcaya, Spain
Read
Not available
Times
was read the article
Total PDF
Total HTML
Share statistics
 array:23 [
  "pii" => "S2253808924000922"
  "issn" => "22538089"
  "doi" => "10.1016/j.remnie.2024.500064"
  "estado" => "S100"
  "fechaPublicacion" => "2024-10-02"
  "aid" => "500064"
  "copyright" => "Sociedad Española de Medicina Nuclear e Imagen Molecular"
  "copyrightAnyo" => "2024"
  "documento" => "article"
  "crossmark" => 0
  "subdocumento" => "fla"
  "abierto" => array:3 [
    "ES" => false
    "ES2" => false
    "LATM" => false
  ]
  "gratuito" => false
  "lecturas" => array:1 [
    "total" => 0
  ]
  "Traduccion" => array:1 [
    "es" => array:18 [
      "pii" => "S2253654X24000957"
      "issn" => "2253654X"
      "doi" => "10.1016/j.remn.2024.500064"
      "estado" => "S200"
      "fechaPublicacion" => "2024-10-09"
      "aid" => "500064"
      "copyright" => "Sociedad Española de Medicina Nuclear e Imagen Molecular"
      "documento" => "article"
      "crossmark" => 0
      "subdocumento" => "fla"
      "abierto" => array:3 [
        "ES" => false
        "ES2" => false
        "LATM" => false
      ]
      "gratuito" => false
      "lecturas" => array:1 [
        "total" => 0
      ]
      "es" => array:12 [
        "idiomaDefecto" => true
        "cabecera" => "<span class="elsevierStyleTextfn">Original</span>"
        "titulo" => "Respuesta&#44; complicaciones y riesgo de transformaci&#243;n leuc&#233;mica del tratamiento con f&#243;sforo-32 en los s&#237;ndromes mieloproliferativos cr&#243;nicos Philadelphia negativos"
        "tienePdf" => "es"
        "tieneTextoCompleto" => "es"
        "tieneResumen" => array:2 [
          0 => "es"
          1 => "en"
        ]
        "titulosAlternativos" => array:1 [
          "en" => array:1 [
            "titulo" => "Response&#44; complications and risk of leukemic transformation of phosphorus-32 treatment in Philadelphia-negative chronic myeloproliferative syndromes"
          ]
        ]
        "contieneResumen" => array:2 [
          "es" => true
          "en" => true
        ]
        "contieneTextoCompleto" => array:1 [
          "es" => true
        ]
        "contienePdf" => array:1 [
          "es" => true
        ]
        "resumenGrafico" => array:2 [
          "original" => 0
          "multimedia" => array:7 [
            "identificador" => "fig0010"
            "etiqueta" => "Figura 2"
            "tipo" => "MULTIMEDIAFIGURA"
            "mostrarFloat" => true
            "mostrarDisplay" => false
            "figura" => array:1 [
              0 => array:4 [
                "imagen" => "gr2.jpeg"
                "Alto" => 1491
                "Ancho" => 1487
                "Tamanyo" => 104903
              ]
            ]
            "descripcion" => array:1 [
              "es" => "<p id="spar0050" class="elsevierStyleSimplePara elsevierViewall">Seguimiento y retratamiento con <span class="elsevierStyleSup">32</span>P&#46;</p>"
            ]
          ]
        ]
        "autores" => array:1 [
          0 => array:2 [
            "autoresLista" => "I&#46; Tobalina Larrea, J&#46; Cuetos Fern&#225;ndez, A&#46; Mendizabal Abad, A&#46; Montero de la Pe&#241;a, D&#46; Garc&#237;a Hern&#225;ndez, G&#46;H&#46; Portilla Quatrociocchi, M&#46; Jim&#233;nez Alonso, M&#46;C&#46; Menchaca Echevarria"
            "autores" => array:8 [
              0 => array:2 [
                "nombre" => "I&#46;"
                "apellidos" => "Tobalina Larrea"
              ]
              1 => array:2 [
                "nombre" => "J&#46;"
                "apellidos" => "Cuetos Fern&#225;ndez"
              ]
              2 => array:2 [
                "nombre" => "A&#46;"
                "apellidos" => "Mendizabal Abad"
              ]
              3 => array:2 [
                "nombre" => "A&#46;"
                "apellidos" => "Montero de la Pe&#241;a"
              ]
              4 => array:2 [
                "nombre" => "D&#46;"
                "apellidos" => "Garc&#237;a Hern&#225;ndez"
              ]
              5 => array:2 [
                "nombre" => "G&#46;H&#46;"
                "apellidos" => "Portilla Quatrociocchi"
              ]
              6 => array:2 [
                "nombre" => "M&#46;"
                "apellidos" => "Jim&#233;nez Alonso"
              ]
              7 => array:2 [
                "nombre" => "M&#46;C&#46;"
                "apellidos" => "Menchaca Echevarria"
              ]
            ]
          ]
        ]
      ]
      "idiomaDefecto" => "es"
      "Traduccion" => array:1 [
        "en" => array:9 [
          "pii" => "S2253808924000922"
          "doi" => "10.1016/j.remnie.2024.500064"
          "estado" => "S100"
          "subdocumento" => ""
          "abierto" => array:3 [
            "ES" => false
            "ES2" => false
            "LATM" => false
          ]
          "gratuito" => false
          "lecturas" => array:1 [
            "total" => 0
          ]
          "idiomaDefecto" => "en"
          "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2253808924000922?idApp=UINPBA00004N"
        ]
      ]
      "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2253654X24000957?idApp=UINPBA00004N"
      "url" => "/2253654X/unassign/S2253654X24000957/v1_202410091021/es/main.assets"
    ]
  ]
  "itemSiguiente" => array:16 [
    "pii" => "S2253808924000971"
    "issn" => "22538089"
    "doi" => "10.1016/j.remnie.2024.500068"
    "estado" => "S200"
    "fechaPublicacion" => "2024-10-06"
    "aid" => "500068"
    "documento" => "article"
    "crossmark" => 0
    "subdocumento" => "sco"
    "abierto" => array:3 [
      "ES" => false
      "ES2" => false
      "LATM" => false
    ]
    "gratuito" => false
    "lecturas" => array:1 [
      "total" => 0
    ]
    "en" => array:10 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Interesting images</span>"
      "titulo" => "Use of propranolol in &#91;<span class="elsevierStyleSup">18</span>F&#93; FDG-PET&#47;CT for differential diagnosis of brown fat in patient with a history of adenocarcinoma of the uterine cervix"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "Uso de propranolol en &#91;<span class="elsevierStyleSup">18</span>F&#93;FDG-PET&#47;TC para diagn&#243;stico diferencial de grasa parda en paciente con antecedente de adenocarcinoma de c&#233;rvix uterino"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:8 [
          "identificador" => "fig0005"
          "etiqueta" => "Figure 1"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "gr1.jpeg"
              "Alto" => 1443
              "Ancho" => 1733
              "Tamanyo" => 218843
            ]
          ]
          "detalles" => array:1 [
            0 => array:3 [
              "identificador" => "at0005"
              "detalle" => "Figure "
              "rol" => "short"
            ]
          ]
          "descripcion" => array:1 [
            "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">&#91;<span class="elsevierStyleSup">18</span>F&#93;FDG PET&#47;CT staging and follow-up at 3 and 6 months post-treatment&#44; section at the level of the pelvis&#46; A&#41; PET&#47;CT fusion prior to the start of treatment&#46; Hyperuptake is observed in the cervix &#40;white circle&#41;&#46; B&#41; CT with cervical tumor lesion&#46; C&#59;E&#41; PET&#47;CT fusion at 3 and 6 months respectively&#44; showing metabolic response &#40;dotted circles&#41;&#46; D&#59;F&#41; Follow-up CT with disappearance of the tumor mass&#46;</p>"
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "A&#46; Garcia Garcia, A&#46;P&#46; Caresia Ar&#243;ztegui, S&#46; Mart&#237;nez Rom&#225;n"
          "autores" => array:3 [
            0 => array:2 [
              "nombre" => "A&#46;"
              "apellidos" => "Garcia Garcia"
            ]
            1 => array:2 [
              "nombre" => "A&#46;P&#46;"
              "apellidos" => "Caresia Ar&#243;ztegui"
            ]
            2 => array:2 [
              "nombre" => "S&#46;"
              "apellidos" => "Mart&#237;nez Rom&#225;n"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2253808924000971?idApp=UINPBA00004N"
    "url" => "/22538089/unassign/S2253808924000971/v1_202410061014/en/main.assets"
  ]
  "itemAnterior" => array:18 [
    "pii" => "S225380892400051X"
    "issn" => "22538089"
    "doi" => "10.1016/j.remnie.2024.500038"
    "estado" => "S200"
    "fechaPublicacion" => "2024-07-11"
    "aid" => "500038"
    "copyright" => "Sociedad Espa&#241;ola de Medicina Nuclear e Imagen Molecular"
    "documento" => "article"
    "crossmark" => 0
    "subdocumento" => "sco"
    "abierto" => array:3 [
      "ES" => false
      "ES2" => false
      "LATM" => false
    ]
    "gratuito" => false
    "lecturas" => array:1 [
      "total" => 0
    ]
    "en" => array:10 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Interesting images</span>"
      "titulo" => "Cardiovascular &#91;<span class="elsevierStyleSup">18</span>F&#93;F-FDG PET&#47;MRI in the diagnosis of acute cardiomyopathy inflammatory"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "PET&#47;RM cardiovascular con &#91;<span class="elsevierStyleSup">18</span>F&#93;F-FDG en el diagn&#243;stico de miocardiopatia aguda inflamatoria"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:8 [
          "identificador" => "fig0010"
          "etiqueta" => "Figure 2"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "gr2.jpeg"
              "Alto" => 1209
              "Ancho" => 850
              "Tamanyo" => 88787
            ]
          ]
          "detalles" => array:1 [
            0 => array:3 [
              "identificador" => "at0010"
              "detalle" => "Figure "
              "rol" => "short"
            ]
          ]
          "descripcion" => array:1 [
            "en" => "<p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">Axial PET&#47;MR fusion images and axial CMR black blood sequences&#46;</p> <p id="spar0025" class="elsevierStyleSimplePara elsevierViewall">Hyperuptake of &#91;<span class="elsevierStyleSup">18</span>F&#93;F-FDG in lower mid-apical segments and apex of LV which is thickened on CMR &#40;A&#41;&#44; with active focus on the anterior wall of the right ventricle&#44; with slight thickening on CMR &#40;B&#41; and hyperuptake of the tracer in the left appendage&#44; without practical translation in CMR &#40;C&#41;&#46;</p> <p id="spar0030" class="elsevierStyleSimplePara elsevierViewall">Axial PET&#47;MR fusion images and axial CMR black blood sequences&#46;</p> <p id="spar0035" class="elsevierStyleSimplePara elsevierViewall">Hyperuptake of &#91;<span class="elsevierStyleSup">18</span>F&#93;F-FDG in lower mid-apical segments and apex of LV wich is thickened on CMR &#40;A&#41;&#44; with active focus on the anterior wall of the right ventricle&#44; with slight thickening on CMR &#40;B&#41; and hyperuptake of the tracer in the left appendage&#44; without practical translation in CMR &#40;C&#41;&#46;</p>"
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "J&#46;R&#46; Garcia, R&#46; Olivero, M&#46; Panelo, L&#46; Mont, L&#46; Pinilla, M&#46;E&#46; Riera, A&#46; Maceira"
          "autores" => array:7 [
            0 => array:2 [
              "nombre" => "J&#46;R&#46;"
              "apellidos" => "Garcia"
            ]
            1 => array:2 [
              "nombre" => "R&#46;"
              "apellidos" => "Olivero"
            ]
            2 => array:2 [
              "nombre" => "M&#46;"
              "apellidos" => "Panelo"
            ]
            3 => array:2 [
              "nombre" => "L&#46;"
              "apellidos" => "Mont"
            ]
            4 => array:2 [
              "nombre" => "L&#46;"
              "apellidos" => "Pinilla"
            ]
            5 => array:2 [
              "nombre" => "M&#46;E&#46;"
              "apellidos" => "Riera"
            ]
            6 => array:2 [
              "nombre" => "A&#46;"
              "apellidos" => "Maceira"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "Traduccion" => array:1 [
      "es" => array:9 [
        "pii" => "S2253654X24000519"
        "doi" => "10.1016/j.remn.2024.500038"
        "estado" => "S200"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => false
          "ES2" => false
          "LATM" => false
        ]
        "gratuito" => false
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "es"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2253654X24000519?idApp=UINPBA00004N"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S225380892400051X?idApp=UINPBA00004N"
    "url" => "/22538089/unassign/S225380892400051X/v1_202407110420/en/main.assets"
  ]
  "en" => array:18 [
    "idiomaDefecto" => true
    "cabecera" => "<span class="elsevierStyleTextfn">Original Article</span>"
    "titulo" => "Response&#44; complications and risk of leukemic transformation of phosphorus-32p treatment in philadelphia-negative chronic myeloproliferative syndromes"
    "tieneTextoCompleto" => true
    "autores" => array:1 [
      0 => array:4 [
        "autoresLista" => "I&#46; Tobalina Larrea, J&#46; Cuetos Fern&#225;ndez, A&#46; Mendizabal Abad, A&#46; Montero de la Pe&#241;a, D&#46; Garc&#237;a Hern&#225;ndez, G&#46;H&#46; Portilla Quatrociocchi, M&#46; Jim&#233;nez Alonso, M&#46;C&#46; Menchaca Echevarria"
        "autores" => array:8 [
          0 => array:4 [
            "nombre" => "I&#46;"
            "apellidos" => "Tobalina Larrea"
            "email" => array:1 [
              0 => "ignacio.tobalinalarrea@osakidetza.eus"
            ]
            "referencia" => array:3 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "aff0005"
              ]
              1 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "aff0010"
              ]
              2 => array:2 [
                "etiqueta" => "&#42;"
                "identificador" => "cor0005"
              ]
            ]
          ]
          1 => array:3 [
            "nombre" => "J&#46;"
            "apellidos" => "Cuetos Fern&#225;ndez"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">c</span>"
                "identificador" => "aff0015"
              ]
            ]
          ]
          2 => array:3 [
            "nombre" => "A&#46;"
            "apellidos" => "Mendizabal Abad"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">d</span>"
                "identificador" => "aff0020"
              ]
            ]
          ]
          3 => array:3 [
            "nombre" => "A&#46;"
            "apellidos" => "Montero de la Pe&#241;a"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "aff0005"
              ]
            ]
          ]
          4 => array:3 [
            "nombre" => "D&#46;"
            "apellidos" => "Garc&#237;a Hern&#225;ndez"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "aff0005"
              ]
            ]
          ]
          5 => array:3 [
            "nombre" => "G&#46;H&#46;"
            "apellidos" => "Portilla Quatrociocchi"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">e</span>"
                "identificador" => "aff0025"
              ]
            ]
          ]
          6 => array:3 [
            "nombre" => "M&#46;"
            "apellidos" => "Jim&#233;nez Alonso"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">e</span>"
                "identificador" => "aff0025"
              ]
            ]
          ]
          7 => array:3 [
            "nombre" => "M&#46;C&#46;"
            "apellidos" => "Menchaca Echevarria"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">d</span>"
                "identificador" => "aff0020"
              ]
            ]
          ]
        ]
        "afiliaciones" => array:5 [
          0 => array:3 [
            "entidad" => "Servicio de Medicina Nuclear&#44; Hospital Universitario de &#193;lava&#44; Osakidetza&#44; Vitoria-Gasteiz&#44; &#193;lava&#44; Spain"
            "etiqueta" => "a"
            "identificador" => "aff0005"
          ]
          1 => array:3 [
            "entidad" => "Facultad de Medicina&#44; Departamento de Cirug&#237;a&#44; Radiolog&#237;a y Medicina F&#237;sica&#44; Universidad del Pa&#237;s Vasco&#44; UPV&#47;EHU&#44; Unidad Docente de Vitoria-Gasteiz&#44; Vitoria-Gasteiz&#44; &#193;lava&#44; Spain"
            "etiqueta" => "b"
            "identificador" => "aff0010"
          ]
          2 => array:3 [
            "entidad" => "Servicio de Radiolog&#237;a&#44; Hospital Universitario Donostia&#44; Osakidetza&#44; Donostia-San Sebasti&#225;n&#44; Guip&#250;zcoa&#44; Spain"
            "etiqueta" => "c"
            "identificador" => "aff0015"
          ]
          3 => array:3 [
            "entidad" => "Servicio de Hematolog&#237;a y Hemoterapia&#44; Hospital Universitario de &#193;lava&#44; Osakidetza&#44; Vitoria-Gasteiz&#44; &#193;lava&#44; Spain"
            "etiqueta" => "d"
            "identificador" => "aff0020"
          ]
          4 => array:3 [
            "entidad" => "Servicio de Medicina Nuclear&#44; Hospital Universitario de Cruces&#44; Osakidetza&#44; Baracaldo-Cruces&#44; Vizcaya&#44; Spain"
            "etiqueta" => "e"
            "identificador" => "aff0025"
          ]
        ]
        "correspondencia" => array:1 [
          0 => array:3 [
            "identificador" => "cor0005"
            "etiqueta" => "&#8270;"
            "correspondencia" => "Corresponding author&#46;"
          ]
        ]
      ]
    ]
    "titulosAlternativos" => array:1 [
      "es" => array:1 [
        "titulo" => "Respuesta&#44; complicaciones y riesgo de transformaci&#243;n leuc&#233;mica del tratamiento con f&#243;sforo-32p en los s&#237;ndromes mieloproliferativos cr&#243;nicos philadelphia negativos&#46;"
      ]
    ]
    "resumenGrafico" => array:2 [
      "original" => 0
      "multimedia" => array:8 [
        "identificador" => "fig0005"
        "etiqueta" => "Figure 1"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr1.jpeg"
            "Alto" => 1199
            "Ancho" => 1591
            "Tamanyo" => 93610
          ]
        ]
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at0005"
            "detalle" => "Figure "
            "rol" => "short"
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Tipo de respuesta a la primera dosis de <span class="elsevierStyleSup">32</span>P&#46;</p>"
        ]
      ]
    ]
    "textoCompleto" => "<span class="elsevierStyleSections"><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0065">Introduction</span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0070">Chronic myeloproliferative syndromes</span><p id="par0005" class="elsevierStylePara elsevierViewall">Chronic myeloproliferative syndromes &#40;MPS&#41; are disorders of clonal hematopoiesis characterized by the proliferation of one or more myeloid lines in the bone marrow&#46; At present&#44; the World Health Organization &#40;WHO&#41; classifies these syndromes based on the series affected as well as the molecular alterations presented&#46;<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a> Polycythemia vera &#40;PV&#41; and essential thrombocythemia &#40;ET&#41; are considered chronic Philadelphia-negative &#40;Phi-&#41; MPS in contrast to other types of entities&#44; such as chronic myeloid leukemia&#44; which is positive for the Philadelphia chromosome &#40;t 9&#58;22&#41;&#46;<a class="elsevierStyleCrossRef" href="#bib0010"><span class="elsevierStyleSup">2</span></a></p><p id="par0010" class="elsevierStylePara elsevierViewall">The incidence of PV in the European Union is 0&#46;4&#8211;2&#46;8&#47;100&#44;000 inhabitants&#47;year&#44; with a mean age at diagnosis of 61 years and a male&#58;female ratio of 1&#58;1&#46;<a class="elsevierStyleCrossRefs" href="#bib0015"><span class="elsevierStyleSup">3&#44;4</span></a> In the case of ET&#44; the estimated incidence is of 0&#46;38&#47;100&#44;000 inhabitants&#47;year&#44; with a mean age of 60 years at diagnosis and with a ratio of female predominance of 2&#58;1&#46;<a class="elsevierStyleCrossRefs" href="#bib0020"><span class="elsevierStyleSup">4&#44;5</span></a></p><p id="par0015" class="elsevierStylePara elsevierViewall">Three major criteria are taken into account for the diagnosis of PV &#40;elevated hemoglobin or hematocrit values&#44; bone marrow biopsy showing hypercellularity and detection of activating mutation in JAK2&#44; exon 14 or 12&#41; and a minor criterium &#40;serum erythropoietin values below the reference level&#41;&#46; For the diagnosis of PV the presence of the three major criteria or two major criteria and the minor criterium is necessary&#46;<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a> In the case of ET&#44; 4 major criteria have been established &#40;thrombocytopenia&#44; bone marrow biopsy with proliferation of the megakaryocytic line&#44; ruling out other myeloproliferative syndromes and detection of a JAK2 mutation &#8211; exon 14 &#8211; CALR or MPL&#41; and a minor criterium &#40;having a clonal marker or absence of reactive thrombocytosis&#41;&#46; To establish the diagnosis of ET&#44; the presence of the 4 major criteria or the first 3 major criteria plus the minor criterium is necessary&#46;<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a></p><p id="par0020" class="elsevierStylePara elsevierViewall">The discovery of the activating mutation in JAK2 exon 14 &#40;V167&#8239;F&#41;&#44; a tyrosine kinase used by hematopoietic cell receptors for erythropoietin&#44; thrombopoietin and the granulocyte colony stimulating factor was an important advance for the diagnosis of the disease and to better understand the underlying physiopathology of the disorder&#46; The JAK2 mutation facilitates the growth and survival of the hematopoietic cells of the clone affected&#46;<a class="elsevierStyleCrossRef" href="#bib0030"><span class="elsevierStyleSup">6</span></a></p><p id="par0025" class="elsevierStylePara elsevierViewall">The clinical manifestations and the complications of PV and ET are related to the elevated cell count in peripheral blood&#46; The elevated erythrocyte count in PV and platelets in ET produces hyperviscosity of the blood that constitutes the major physiopathological phenomenon in the genesis of the clinical manifestations and complications in these patients&#46; The two complications with the greatest morbidity mortality associated with both PV and ET are vascular thrombosis and hemorrhages&#46;<a class="elsevierStyleCrossRefs" href="#bib0015"><span class="elsevierStyleSup">3&#44;7</span></a> Although less frequent&#44; thee is also a risk of evolution to myelofibrosis or acute leukemia &#40;AL&#41;&#46;</p><p id="par0030" class="elsevierStylePara elsevierViewall">Within each entity&#44; patients are stratified into different groups of risk&#46; Patients diagnosed with PV are classified into three groups of low&#44; intermediate or high risk according to the probability of complications&#46; The risk is estimated based on a history of thrombosis&#44; hematimetric data and the age of the patient&#46; The grade of risk allows estimating survival and can guide treatment&#46; In the case of PV&#44; the median survival is 25&#44; 15 and 8&#46;3 years&#44; respectively for each group&#46;<a class="elsevierStyleCrossRef" href="#bib0015"><span class="elsevierStyleSup">3</span></a> To calculate the risk in ET&#44; the International Prognostic Score of thrombosis in World Health Organization essential thrombocythemia &#40;IPSET-thrombosis&#41; is used&#46;<a class="elsevierStyleCrossRef" href="#bib0035"><span class="elsevierStyleSup">7</span></a> In addition to age&#44; this scale takes into account the mutation in the KAK2 V617F gene&#44; a history of thrombosis and the presence of cardiovascular risk factors&#46; The patients are classified into high&#44; intermediate&#44; low and very low risk according to the probability of presenting thrombotic events&#46;<a class="elsevierStyleCrossRef" href="#bib0040"><span class="elsevierStyleSup">8</span></a> In the case of ET&#44; the mean survival with adequate treatment is the same as that of the general population&#46;</p><p id="par0035" class="elsevierStylePara elsevierViewall">The main objectives of treatment are to prevent the appearance of thrombotic and hemorrhagic complications&#44; control associated symptoms&#44; minimize the risk of transformation to AL or myelofibrosis and achieve adequate management in situations of risk such as pregnancy or surgery&#46;<a class="elsevierStyleCrossRefs" href="#bib0015"><span class="elsevierStyleSup">3&#44;8</span></a> Treatment should be personalized taking into account the history of the patient as well as comorbidities and the group of risk of complications to which the patient pertains&#46; At present&#44; there are numerous therapeutic options&#58; phlebotomy for maintaining hematocrit levels &#60; 45&#37;&#44; platelet&#44; antiplatelet agents for preventing thrombotic events&#58; hydroxyurea&#44; busulfan&#44; anagrelide&#44; ruxolitinib&#44; pegylated interferon and phosphorus-<span class="elsevierStyleSup">32</span>P &#40;<span class="elsevierStyleSup">32</span>P&#41;&#44; among others&#46;<a class="elsevierStyleCrossRefs" href="#bib0025"><span class="elsevierStyleSup">5&#44;9&#8211;11</span></a> To evaluate response to treatment&#44; the criteria of the European LeukemiaNet and International Working Group are used&#46;<a class="elsevierStyleCrossRef" href="#bib0060"><span class="elsevierStyleSup">12</span></a></p></span><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0075">Phosphorus-<span class="elsevierStyleSup">32</span>P</span><p id="par0040" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleSup">32</span>P is beta particle emitter produced in nuclear reactors with a maximum energy of 1&#46;71 MeV and a mean energy of 0&#46;695 MeV&#46; Its reach in tissue is of 3&#8211;8&#8239;mm and it has a half-life of 14&#46;3 days&#46; <span class="elsevierStyleSup">32</span>P is presented in the form of an injectable solution of sodium orthophosphate&#46; Following injection&#44; it targets tissues with an increase in phosphorus turnover&#44; such as blood stem cells&#44; which are cells in the proliferative phase and have greater protein synthesis&#46; The biological effect of <span class="elsevierStyleSup">32</span>P is based on direct DNA damage by the radiation&#46;<a class="elsevierStyleCrossRef" href="#bib0015"><span class="elsevierStyleSup">3</span></a></p><p id="par0045" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleSup">32</span>P was first used by John H&#46; Lawrence in 1938 for the treatment of PV and AL&#46;<a class="elsevierStyleCrossRef" href="#bib0045"><span class="elsevierStyleSup">9</span></a> The therapeutic application of <span class="elsevierStyleSup">32</span>P began when Lawrence treated the first patient after having observed in his laboratory how this radiopharmaceutical accumulated in the spleen&#44; liver&#44; bone marrow and in leukemic cells&#44; suggesting a possible therapeutic potential against the latter&#46; Later&#44; in 1950&#44; the treatment of ET was also added to these two applications&#46;<a class="elsevierStyleCrossRefs" href="#bib0020"><span class="elsevierStyleSup">4&#8211;15</span></a> However&#44; although <span class="elsevierStyleSup">32</span>P has been approved for the treatment of MPS&#44; over time new drugs have been developed&#44; relegating <span class="elsevierStyleSup">32</span>P to a totally marginal role&#44; overall due to the link between the use of this substance and the development of AL&#46;<a class="elsevierStyleCrossRefs" href="#bib0065"><span class="elsevierStyleSup">13&#8211;21</span></a></p><p id="par0050" class="elsevierStylePara elsevierViewall">The aim of the present study was to review our experience with treatment with <span class="elsevierStyleSup">32</span>P&#44; focusing on response to this radiopharmaceutical and early and late complications in patients presenting intolerance and&#47;or resistance to the usual therapies&#46;</p></span></span><span id="sec0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0080">Material and method</span><span id="sec0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0085">Study design</span><p id="par0055" class="elsevierStylePara elsevierViewall">Retrospective observational study&#46;</p></span><span id="sec0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0090">Study population</span><p id="par0060" class="elsevierStylePara elsevierViewall">The study included all the patients undergoing treatment with <span class="elsevierStyleSup">32</span>P from January 1985 to March 2017&#44; which was the month of the last dose administered in our Nuclear Medicine Department&#46; The inclusion criteria were&#58; age &#62;18 years&#44; diagnosis of chronic Phi- MPS&#44; intolerance or poor control of first line treatments and complete follow-up and analytical data of at least 5 months after the first dose of <span class="elsevierStyleSup">32</span>P&#46; Patients with PV were also required to have been pretreated with phlebotomy until obtaining hematocrit values within the range of 42&#8211;47&#37; prior to administering <span class="elsevierStyleSup">32</span>P&#46;</p><p id="par0065" class="elsevierStylePara elsevierViewall">The exclusion criteria were atients who were or wished to be pregnant and breast feeding&#44; patients with leukocyte counts &#60;2&#44;000&#47;mm<span class="elsevierStyleSup">3</span> and&#44; in the case of ET&#44; a hemoglobin value &#60;9&#8239;g&#47;dl&#46; In addition&#44; patients in whom the clinical and analytical data described in the variable section were not available were excluded from the study&#46;</p><p id="par0070" class="elsevierStylePara elsevierViewall">The last date of the follow-up was the last consultation registered in the clinical history and with a minimum follow-up of 5 months after the last dose of <span class="elsevierStyleSup">32</span>P&#46;</p><p id="par0075" class="elsevierStylePara elsevierViewall">The patients received oral and written information prior to the procedure&#46; This study was approved by the Ethical Committee of Clinical Investigation of &#193;lava &#40;file number&#58; 2015-067&#41; which granted the exemption of obtaining informed consent from the participants&#46;</p></span><span id="sec0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0095">Treatment with phosphorus-<span class="elsevierStyleSup">32</span>P</span><p id="par0080" class="elsevierStylePara elsevierViewall">The radiopharmaceutical was administered slowly via a peripheral venous line&#44; avoiding extravasation&#44; which can induce venous thrombophlebitis or radionecrosis at the injection site&#46; It was administered in the Nuclear Medicine Department by trained and adequately equipped personnel according to the prevailing legislation and with means of action in case of radioactive contamination&#46; Due to the type of radioactive emission&#44; the administration of the radiopharmaceutical does not require the patient to be admitted to an isolation room for radioprotection measures&#46; However&#44; the radiopharmaceutical presents a small percentage of urinary elimination&#44; and thus&#44; hygiene measures related to urination during the first days after treatment are indicated&#46;</p><p id="par0085" class="elsevierStylePara elsevierViewall">The treatment with <span class="elsevierStyleSup">32</span>P was performed according to the international guidelines published in the European Journal of Nuclear Medicine&#44;<a class="elsevierStyleCrossRef" href="#bib0065"><span class="elsevierStyleSup">13</span></a> adjusting the dose to the body surface area&#46; In our patients the dose administered was 74&#8211;111 MBq&#47;m<span class="elsevierStyleSup">2</span>&#46; In cases of inadequate response&#44; the administration of a second dose at least 12 weeks after the first was evaluated&#44; with an increase of 25&#37;&#44; without surpassing 260 MBq&#46; The administration of new doses was also considered in case of relapse or partial response&#46;</p><p id="par0090" class="elsevierStylePara elsevierViewall">The need to reduce the dose administered was evaluated in case of deterioration of renal function and in patients over 80 years of age&#46;<a class="elsevierStyleCrossRef" href="#bib0065"><span class="elsevierStyleSup">13</span></a> Clinical and analytical follow-up was carried out every two weeks after treatment with <span class="elsevierStyleSup">32</span>P to determine for the appearance of side effects&#46; In consensus with a specialist in hematology&#44; the discontinuation or a reduction in the baseline treatment dose was indicated one week after the administration of <span class="elsevierStyleSup">32</span>P&#46;</p></span><span id="sec0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0100">Variables</span><p id="par0095" class="elsevierStylePara elsevierViewall">After identifying all the patients treated with <span class="elsevierStyleSup">32</span>P since January 1985&#44; the clinical histories were reviewed and the following variables were collected&#58; demographic &#40;age at diagnosis of MPS and sex&#41;&#44; anthropometric data &#40;weight&#44; height and body surface&#41;&#44; diagnosis &#40;ET&#44; PV&#41;&#44; MPS treatment&#44; referral criteria for treatment with <span class="elsevierStyleSup">32</span>P &#40;patients with inadequate control and&#47;or poor tolerance to the usual treatment&#41;&#44; analytical variables of renal function and hematimetry &#40;at diagnosis and of follow-up&#41;&#44; treatment with <span class="elsevierStyleSup">32</span>P &#40;dose&#47;date&#44; total dose&#44; type of response&#44; early side effects&#44; need for transfusion of hemoderivatives&#44; follow-up time and late side effects&#44; with special attention to possible leukemic transformation&#41; and associated comorbidity&#46;</p><p id="par0100" class="elsevierStylePara elsevierViewall">The evaluation of response to treatment followed the criteria published by the European LeukemiaNet and International Working Group&#46; According to these criteria&#44; patients with complete response &#40;CR&#41; are those in whom platelet counts &#60;400&#44;000 &#47;mm<span class="elsevierStyleSup">3</span> in ET and hematocrit &#60;45&#37; in cases of PV were observed during at least 12 weeks in the absence of vascular events or progression of the disorder&#46;<a class="elsevierStyleCrossRef" href="#bib0060"><span class="elsevierStyleSup">12</span></a></p></span><span id="sec0045" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0105">Statistical analysis</span><p id="par0105" class="elsevierStylePara elsevierViewall">With the data obtained&#44; descriptive statistical analysis was performed&#46; The categorical variables were expressed as number and percentage&#46; The quantitative variables were described with mean and standard deviation &#40;SD&#41; in the case of normal distribution and with median and interquartile range &#40;IQR&#41; if they followed a non-normal distribution&#46; The distribution of the variables was determined with the Shapiro-Wilk test&#46;</p></span></span><span id="sec0050" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0110">Results</span><p id="par0110" class="elsevierStylePara elsevierViewall">Among the 27 patients treated with <span class="elsevierStyleSup">32</span>P during the time period analyzed&#44; 10 were excluded from the study because the laboratory&#44; clinical and follow-up data defined in the Material and Methods section were not available&#46;</p><p id="par0115" class="elsevierStylePara elsevierViewall">The final sample analyzed was composed of 17 patients treated with <span class="elsevierStyleSup">32</span>P&#59; 64&#46;7&#37; &#40;11&#41; diagnosed with ET and 35&#46;3&#37; &#40;6&#41; diagnosed with PV&#46; With respect to the distribution by sex&#44; 64&#46;7&#37; &#40;11&#41; were men and 35&#46;3&#37; &#40;6&#41; were women&#46; The mean age of the patients was 79&#46;8 years &#40;SD&#58; 6&#44;02&#59; range&#58; 66&#8211;88&#41;&#46; By disease&#44; the mean age in the group diagnosed with PV was 76&#46;6 years &#40;SD&#58; 6&#44;87&#59; range&#58; 66&#8211;85&#41;&#44; being 80 years &#40;SD&#58; 4&#44;67&#59; range&#58; 73&#8211;88&#41; in the ET group&#46; <a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a> shows the characteristics of the patients&#46;</p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia><p id="par0120" class="elsevierStylePara elsevierViewall">Sixteen patients presented associated comorbidity and most &#40;70&#37;&#41; were taking more than one drug in addition to the pharmaceuticals prescribed as treatment of Phi- MPS&#46; Four of the patients referred for treatment with <span class="elsevierStyleSup">32</span>P were not taking baseline medication for Phi- MPS because of treatment withdrawal due to poor tolerance&#44; particularly the appearance of ulcers in mucosa or the lower extremities&#46; Among the remaining patients&#44; 9 received monotherapy &#40;8 with hydroxyurea and 1 with anagrelide&#41;&#44; 2 received combined treatment with anagrelide and hydroxyurea and 2 underwent periodic phlebotomies&#46; Due to the difficulties related to the treatment and&#47;or the adverse effects and poor tolerance&#44; it was decided to refer the patients to the Nuclear Medicine Department to evaluate the administration of <span class="elsevierStyleSup">32</span>P&#46;</p><p id="par0125" class="elsevierStylePara elsevierViewall">The data regarding the treatment with <span class="elsevierStyleSup">32</span>P are summarized in <a class="elsevierStyleCrossRef" href="#tbl0010">Table 2</a>&#46; Only one dose of <span class="elsevierStyleSup">32</span>P was received by 52&#46;9&#37; &#40;9&#47;17&#41; of the subjects&#44; while 47&#37; &#40;8&#47;17&#41; required two or more doses due to inadequate hematological response and&#47;or relapse&#46; The range of the total dose of <span class="elsevierStyleSup">32</span>P administered was between 116 and 951 MBq&#44; with a median of 236 MBq &#40;IQR&#58;185&#8722;360&#41;&#46;</p><elsevierMultimedia ident="tbl0010"></elsevierMultimedia><p id="par0130" class="elsevierStylePara elsevierViewall">The median follow-up of the patients from the date of the first treatment with <span class="elsevierStyleSup">32</span>P to finalization of the study or death was 37 months &#40;range&#58; 5&#8211;230 months&#59; IQR&#58; 29&#8211;75&#41; &#40;<a class="elsevierStyleCrossRef" href="#tbl0010">Table 2</a>&#41;&#46;</p><span id="sec0055" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0115">Type of response</span><p id="par0135" class="elsevierStylePara elsevierViewall">As shown in <a class="elsevierStyleCrossRef" href="#tbl0010">Table 2</a>&#44; of the 17 patients&#44; 82&#46;3&#37; &#40;14&#41; presented complete response &#40;CR&#41; or partial response &#40;PR&#41; in the hemogram after the first dose of <span class="elsevierStyleSup">32</span>P&#46; Among the sample&#44; 11 patients &#40;11&#47;14&#41; presented CR and in 8 of these patients CR was achieved with the first dose of <span class="elsevierStyleSup">32</span>P&#46; Three patients &#40;3&#47;14&#41;&#44; all diagnosed with ET&#44; presented PR with a reduction in platelet levels but without achieving values &#60;400&#44;000&#47;mm<span class="elsevierStyleSup">3</span>&#46; No response was observed in 17&#46;6&#37; &#40;3&#41; of the patients &#40;<a class="elsevierStyleCrossRef" href="#fig0005">Fig&#46; 1</a>&#41;&#46;</p><elsevierMultimedia ident="fig0005"></elsevierMultimedia><p id="par0140" class="elsevierStylePara elsevierViewall">Among the 11 patients with CR&#44; the response was maintained in 5 &#40;45&#46;4&#37;&#41;&#44; with a median follow-up of 25 months &#40;range&#58; 5&#8211;38 months&#59; IQR&#58; 9&#8211;37&#41;&#46; Four patients &#40;36&#46;4&#37;&#41; required the administration of a second or more doses of <span class="elsevierStyleSup">32</span>P to again achieve CR&#46; In the other 2 patients &#40;18&#46;2&#37;&#41;&#44; it was decided not to repeat the dose of <span class="elsevierStyleSup">32</span>P&#59; in one due to early relapse and in the other because baseline treatment could not be suspended &#40;<a class="elsevierStyleCrossRef" href="#fig0010">Fig&#46; 2</a>&#41;&#46;</p><elsevierMultimedia ident="fig0010"></elsevierMultimedia></span><span id="sec0060" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0120">Early and late complications related to treatment with <span class="elsevierStyleSup">32</span>P</span><p id="par0145" class="elsevierStylePara elsevierViewall"><a class="elsevierStyleCrossRef" href="#tbl0010">Table 2</a> shows the early and late complications identified in relation to treatment with <span class="elsevierStyleSup">32</span>P&#46; Three patients &#40;17&#46;6&#37;&#41; presented early complications&#44; all of which were hematological&#46; In 2 of the subjects&#44; anemia was found requiring blood transfusion&#59; one presented hemoglobin values lower than normal before treatment with <span class="elsevierStyleSup">32</span>P&#46; On the other hand&#44; 1 patient with PV developed mild thrombopenia that did not require specific treatment&#46;</p><p id="par0150" class="elsevierStylePara elsevierViewall">During the follow-up period&#44; no case of leukemic transformation was diagnosed in any of the patients&#46; One 75-year-old male who received a single dose of 199 MBq of <span class="elsevierStyleSup">32</span>P for being diagnosed with ET with poor control with hydroxyurea&#44; associated comorbidity &#40;ischemic cardiopathy and Alzheimer disease&#41; and polymedication&#44; developed W&#228;ldestrom disease&#46; It should be noted that before the administration of <span class="elsevierStyleSup">32</span>P&#44; the patient was followed due to elevation of monoclonal IgM Kappa&#46; This patient showed good response to treatment associated with an episode of anemia following the radiophohphorus treatment and required blood transfusion&#46;</p></span><span id="sec0065" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0125">Mortality</span><p id="par0155" class="elsevierStylePara elsevierViewall">Fifteen patients in our cohort died during follow-up&#46; No death was related to <span class="elsevierStyleSup">32</span>P treatment&#46; With respect to mortality&#44; in 26&#46;7&#37; &#40;4&#47;15&#41; of the cases&#44; death was related to complications of the MDS and&#47;or treatment of MDS&#46; These 4 cases corresponded to 1 death within the context of a splenic infarction and 3 deaths were the consequence of respiratory infections&#46; In 2 cases &#40;2&#47;15&#41;&#44; the cause of death could not be clarified&#44; although death due to <span class="elsevierStyleSup">32</span>P treatment or leukemic transformation was not suspected in either of these patients&#46; The remaining known causes of death &#40;9&#47;15&#41; were&#58; 1 death within the context of renal failure with hyperpotassemia and with leukocytosis with no blasts observed&#44; 1 case of death related to the development of a hepatocarcinoma within the context of hepatic cirrhosis&#44; 2 associated with renal insufficiency&#44; 1 as a consequence of acute respiratory failure&#44; 1 due to rupture of a pseudoaneurysm&#44; 2 within the context of multiorgan failure due to pluripathology and 1 due to congestive heart failure with acute hypercapnic respiratory failure&#46; The evolution of the other 2 patients was unknown after 37 and 38 months of follow-up after the first treatment with <span class="elsevierStyleSup">32</span>P&#46;</p></span></span><span id="sec0070" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0130">Discussion</span><p id="par0160" class="elsevierStylePara elsevierViewall">The side effects of <span class="elsevierStyleSup">32</span>P treatment can be divided into early and late&#46; Among the early side effect&#44; those related to myelosuppression &#40;leukopenia&#44; thrombocytopenia and anemia&#41; are of note and usually appear at 4&#8211;6 weeks after administration of <span class="elsevierStyleSup">32</span>P and spontaneously resolve within 4 months&#46; It is fundamental to perform a hematimetric study to rule out these early complications&#44; which may require specific treatment&#46; In our series&#44; early complications were observed in 3 patients&#44; all due to myelosuppression&#44; which in 2 cases required blood transfusion&#46;</p><p id="par0165" class="elsevierStylePara elsevierViewall">Among the possible late complications of chronic MPS there is the risk of developing AL&#46; Leukemic transformation is associated with a bad prognosis and very high mortality&#46; With respect to the factors associated with this risk of leukemic transformation&#44; the first is the subtype of MPS&#46; In patients with primary myelofibrosis the risk is 10&#8211;20&#37; at 10 years&#46; In patients diagnosed with PV&#44; the estimated risk is 2&#46;3&#37; at 10 years and 7&#46;9&#37; at 20 years&#46; In the case of ET&#44; after the modification of the 2016 WHO diagnostic criteria&#44;<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a> the risk is 1&#37; at 10 years and 2&#37; at 15 years&#46;<a class="elsevierStyleCrossRefs" href="#bib0080"><span class="elsevierStyleSup">16&#44;18&#8211;21</span></a> In 2019&#44; Szuber et al&#46;<a class="elsevierStyleCrossRef" href="#bib0100"><span class="elsevierStyleSup">20</span></a> published a series from the Mayo Clinic that included 1&#44;076 patients diagnosed with ET and 665 patients with PV&#46; One of the most notable conclusions of this study was the similar incidence of 4&#37; of blast transformation in not only patients diagnosed with ET but also in those with PV&#46; The mean time to leukemic transformation was 11 years for patients with ET and 10 years for those with PV&#46; The authors noted the need to stratify individual risk to adapt the treatment and establish the prognosis of each patient&#46; The controversy regarding whether the morbidity mortality associated with ET can be attributed to inadequately classified cases of prefibrotic phases of myelofibrosis should also be taken into account&#46; Different authors&#44; such as McKinnell et al&#46;&#44;<a class="elsevierStyleCrossRef" href="#bib0105"><span class="elsevierStyleSup">21</span></a> Tefferi et al&#46;<a class="elsevierStyleCrossRef" href="#bib0110"><span class="elsevierStyleSup">22</span></a> and Dunvar et al&#46;&#44;<a class="elsevierStyleCrossRef" href="#bib0115"><span class="elsevierStyleSup">23</span></a> established the risk factors involved in the leukemic transformation of MPS&#46; Clinical data including age&#44; the need for transfusions&#44; the type of previous treatment &#40;pipobroman&#44; <span class="elsevierStyleSup">32</span>P&#44; chlorambucil and busulfan&#41;&#44; laboratory data&#44; such as the presence of leukocytosis&#44; anemia&#44; thrombocytopenia&#44; extreme thrombocytosis&#44; the presence of blasts in peripheral blood&#44; inflammatory cytokines and elevation of C-reactive protein&#44; as well as cytogenetic and molecular data&#44; were among the factors identified&#46;</p><p id="par0170" class="elsevierStylePara elsevierViewall">With respect to the development of AL in patients treated with <span class="elsevierStyleSup">32</span>P&#44; different studies have analyzed the role of <span class="elsevierStyleSup">32</span>P&#46; In the prospective study by Finazzi et al&#46;<a class="elsevierStyleCrossRef" href="#bib0085"><span class="elsevierStyleSup">17</span></a> including 1638 patients diagnosed with PV&#44; 22 subjects &#40;1&#46;34&#37;&#41; developed AL or a myelodysplastic syndrome &#40;MDS&#41;&#46; It is assumed that patients treated only with phlebotomy or treatment with interferon are the control group that would represent the natural risk of developing these complications in the evolution of patients with PV&#46; In this study&#44; the patients only treated with hydroxyurea did not have a greater risk than the control group estimated at 0&#46;29&#47;100 persons and year &#40;hazard ratio &#91;HR&#93; 0&#46;86&#59; 95&#37; confidence interval &#91;CI&#93; 0&#46;26&#8211;2&#46;88&#41;&#46; However&#44; in patients treated with pipobroman&#44; busulfan and with <span class="elsevierStyleSup">32</span>P alone or in combination with hydroxyurea&#44; the risk increased to 1&#46;8&#47;100 persons and year &#40;HR 5&#46;46&#59; 95&#37; CI 1&#46;84&#8211;16&#46;25&#41;&#46; In 2005&#44; McMullin et al&#46;<a class="elsevierStyleCrossRef" href="#bib0120"><span class="elsevierStyleSup">24</span></a> published a review of randomized clinical trials of different treatments in PV&#46; In the trials that included treatment with <span class="elsevierStyleSup">32</span>P&#44; the risk of developing AL at 10 years was established at between 9&#46;6 and 12&#37; for non-combined treatment and this risk increased to 20&#37; with treatment associated with hydroxyurea&#46; In the case of therapy with chlorambucil&#44; the estimated risk was 13&#46;5&#37; at 10 years and 1&#46;5&#37; for those treated with phlebotomy&#46;<a class="elsevierStyleCrossRefs" href="#bib0125"><span class="elsevierStyleSup">25&#8211;29</span></a> Brandt et al&#46;<a class="elsevierStyleCrossRef" href="#bib0130"><span class="elsevierStyleSup">26</span></a> analyzed the probability of the appearance of AL in the treatment with radioactive phosphorus of PV and ET&#46; Of the 366 patients initially included&#44; 107 were followed for more than 10 years&#44; with 10&#46;3&#37; developing AL&#46; The mean time to leukemic transformation was 8&#46;5 years from the initiation of treatment and was not related to the dose of <span class="elsevierStyleSup">32</span>P administered&#46; In 2011&#44; Bjorkhokm et al&#46;<a class="elsevierStyleCrossRef" href="#bib0145"><span class="elsevierStyleSup">29</span></a> studied what percentage of cytoreductive therapies contributed to the posterior development of AL or MDS in a Swedish population&#46; They concluded that 25&#37; of the patients who presented transformation to AL or MDS had not received treatment with <span class="elsevierStyleSup">32</span>P&#44; hydroxyurea or alkylating agents&#46; They also concluded that the risk of transformation to AL was associated with the cumulative dose of <span class="elsevierStyleSup">32</span>P&#46; In doses greater than or equal to 1&#44;000 MBq an odds ratio of 4&#46;8 &#40;2&#8211;9&#46;9&#59; 95&#37; CI&#41; was obtained&#46; Another study by Randi et al&#46;<a class="elsevierStyleCrossRef" href="#bib0075"><span class="elsevierStyleSup">15</span></a> was aimed at the possible complications after treatment with <span class="elsevierStyleSup">32</span>P in 230 patients with MPS&#46; None of the patients presenting ET developed AL transformation and among those diagnosed with PV&#44; 2&#46;3&#37; &#40;5&#47;214&#41; developed AL&#46; Balan and Critchley<a class="elsevierStyleCrossRef" href="#bib0135"><span class="elsevierStyleSup">27</span></a> published a retrospective study of 238 patients treated with <span class="elsevierStyleSup">32</span>P&#44; with a mean dose of 496 MBq&#44; with a range between 81&#46;4 and 4&#46;162 MBq&#46; They reported that 7&#46;6&#37; &#40;18&#47;236&#41; of the patients&#44; 13 diagnosed with PV and 5 with ET&#44; developed AL within a period of between 2 and 11 years after the administration of the first dose of <span class="elsevierStyleSup">32</span>P&#46; Lastly&#44; in 2016&#44; Lawless et al&#46;<a class="elsevierStyleCrossRef" href="#bib0150"><span class="elsevierStyleSup">30</span></a> published a retrospective revision of 19 patients&#44; 15 diagnosed with ET and 4 with PV treated with radioactive phosphorus between 1988 and 2012&#44; with a mean follow-up of 22 months&#44; during which no patient was diagnosed with AL&#46; They concluded that treatment with radioactive phosphorus was effective in 90&#37; of the patients treated and they did not observe any case of thrombosis&#44; myelofibrosis or AL&#46;</p><p id="par0175" class="elsevierStylePara elsevierViewall">The variability of the results in the literature regarding the risk of leukemization in patients treated with <span class="elsevierStyleSup">32</span>P may be due to the multiple factors identified in the last years which influence leukemic transformation in MPS&#46;<a class="elsevierStyleCrossRefs" href="#bib0100"><span class="elsevierStyleSup">20&#8211;23</span></a> A meta-analysis is necessary to determine the real impact of the treatments&#44; including <span class="elsevierStyleSup">32</span>P&#44; on the risk of leukemic transformation after stratifying the patients by clinical data&#44; analytical data&#44; the presence of inflammatory cytokines&#44; elevation of C-reactive protein as well as cytogenetic and molecular data&#46;</p><p id="par0180" class="elsevierStylePara elsevierViewall">In our sample a high percentage of CR or PR to treatment with <span class="elsevierStyleSup">32</span>P was observed&#44; with mild early side effects and no leukemic transformation during follow-up&#46;</p><p id="par0185" class="elsevierStylePara elsevierViewall">In the last years interest in metabolic radiotherapy has increased&#44; including the therapeutic application of <span class="elsevierStyleSup">32</span>P as well as brachytherapy in patients diagnosed with non-resectable adenocarcinoma of the pancreas&#46;<a class="elsevierStyleCrossRef" href="#bib0155"><span class="elsevierStyleSup">31</span></a> A return to the therapeutic applications of <span class="elsevierStyleSup">32</span>P in clinical practice may facilitate its use in some patients with chronic MPS with poor tolerance or without response to the usual treatments and with a low risk of leukemic transformation&#46; Unfortunately&#44; <span class="elsevierStyleSup">32</span>P is not available in the form of an injectable solution of sodium orthophosphate&#46;</p><p id="par0190" class="elsevierStylePara elsevierViewall">Among the limitations of the present study there is the small sample size&#44; which does not allow obtaining statistically significant results&#46; On the other hand&#44; of the 27 patients identified in the initial recruitment&#44; 10 were excluded from the study because the necessary analytical&#44; clinical and follow-up data were not available&#46; In addition&#44; the coding of the mutations involved in chronic MPS &#40;currently present in the diagnostic criteria&#41;&#44; such as the JAK2 mutation&#44; was not performed at diagnosis in the first years included in the series&#44; thereby limiting the prognostic stratification of our patients&#46;</p><p id="par0195" class="elsevierStylePara elsevierViewall">In conclusion&#44; in our experience&#44; treatment with phophorus-<span class="elsevierStyleSup">32</span>P has shown to be a useful therapeutic option in Philadelphia-negative chronic myeloproliferative syndrome in elderly patients with poor tolerance and&#47;or resistance to first line treatment&#46; We did not identify any case of leukemic transformation&#46;</p></span><span id="sec0075" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0135">Conflict of interest</span><p id="par0200" class="elsevierStylePara elsevierViewall">The authors declare that they have no conflict of interest&#46;</p></span></span>"
    "textoCompletoSecciones" => array:1 [
      "secciones" => array:10 [
        0 => array:3 [
          "identificador" => "xres2259506"
          "titulo" => "Abstract"
          "secciones" => array:4 [
            0 => array:2 [
              "identificador" => "abst0005"
              "titulo" => "Objective"
            ]
            1 => array:2 [
              "identificador" => "abst0010"
              "titulo" => "Material and methods"
            ]
            2 => array:2 [
              "identificador" => "abst0015"
              "titulo" => "Results"
            ]
            3 => array:2 [
              "identificador" => "abst0020"
              "titulo" => "Conclusions"
            ]
          ]
        ]
        1 => array:2 [
          "identificador" => "xpalclavsec1885737"
          "titulo" => "Keywords"
        ]
        2 => array:3 [
          "identificador" => "xres2259505"
          "titulo" => "Resumen"
          "secciones" => array:4 [
            0 => array:2 [
              "identificador" => "abst0025"
              "titulo" => "Objetivo"
            ]
            1 => array:2 [
              "identificador" => "abst0030"
              "titulo" => "Material y m&#233;todos"
            ]
            2 => array:2 [
              "identificador" => "abst0035"
              "titulo" => "Resultados"
            ]
            3 => array:2 [
              "identificador" => "abst0040"
              "titulo" => "Conclusiones"
            ]
          ]
        ]
        3 => array:2 [
          "identificador" => "xpalclavsec1885736"
          "titulo" => "Palabras clave"
        ]
        4 => array:3 [
          "identificador" => "sec0005"
          "titulo" => "Introduction"
          "secciones" => array:2 [
            0 => array:2 [
              "identificador" => "sec0010"
              "titulo" => "Chronic myeloproliferative syndromes"
            ]
            1 => array:2 [
              "identificador" => "sec0015"
              "titulo" => "Phosphorus-P"
            ]
          ]
        ]
        5 => array:3 [
          "identificador" => "sec0020"
          "titulo" => "Material and method"
          "secciones" => array:5 [
            0 => array:2 [
              "identificador" => "sec0025"
              "titulo" => "Study design"
            ]
            1 => array:2 [
              "identificador" => "sec0030"
              "titulo" => "Study population"
            ]
            2 => array:2 [
              "identificador" => "sec0035"
              "titulo" => "Treatment with phosphorus-P"
            ]
            3 => array:2 [
              "identificador" => "sec0040"
              "titulo" => "Variables"
            ]
            4 => array:2 [
              "identificador" => "sec0045"
              "titulo" => "Statistical analysis"
            ]
          ]
        ]
        6 => array:3 [
          "identificador" => "sec0050"
          "titulo" => "Results"
          "secciones" => array:3 [
            0 => array:2 [
              "identificador" => "sec0055"
              "titulo" => "Type of response"
            ]
            1 => array:2 [
              "identificador" => "sec0060"
              "titulo" => "Early and late complications related to treatment with P"
            ]
            2 => array:2 [
              "identificador" => "sec0065"
              "titulo" => "Mortality"
            ]
          ]
        ]
        7 => array:2 [
          "identificador" => "sec0070"
          "titulo" => "Discussion"
        ]
        8 => array:2 [
          "identificador" => "sec0075"
          "titulo" => "Conflict of interest"
        ]
        9 => array:1 [
          "titulo" => "References"
        ]
      ]
    ]
    "pdfFichero" => "main.pdf"
    "tienePdf" => true
    "fechaRecibido" => "2024-04-30"
    "fechaAceptado" => "2024-09-15"
    "PalabrasClave" => array:2 [
      "en" => array:1 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Keywords"
          "identificador" => "xpalclavsec1885737"
          "palabras" => array:6 [
            0 => "Phosphorus-<span class="elsevierStyleSup">32</span>P"
            1 => "Radioactive phosphorus"
            2 => "Polycythemia vera"
            3 => "Essential thrombocythemia"
            4 => "Myeloproliferative disorders"
            5 => "Acute leukemia"
          ]
        ]
      ]
      "es" => array:1 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Palabras clave"
          "identificador" => "xpalclavsec1885736"
          "palabras" => array:6 [
            0 => "F&#243;sforo-<span class="elsevierStyleSup">32</span>P"
            1 => "F&#243;sforo radioactivo"
            2 => "Policitemia vera"
            3 => "Trombocitemia esencial"
            4 => "S&#237;ndromes mieloproliferativos"
            5 => "Leucemia aguda"
          ]
        ]
      ]
    ]
    "tieneResumen" => true
    "resumen" => array:2 [
      "en" => array:3 [
        "titulo" => "Abstract"
        "resumen" => "<span id="abst0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0010">Objective</span><p id="spar0025" class="elsevierStyleSimplePara elsevierViewall">Describe our experience in treatment with Phosphorus-32P for refractory Philadelphia negative chronic myeloproliferative syndromes or with side effects to the usual treatment&#44; its complications and risk of leukemic transformation&#46;</p></span> <span id="abst0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0015">Material and methods</span><p id="spar0030" class="elsevierStyleSimplePara elsevierViewall">Retrospective descriptive study including 17 patients with a diagnosis of Philadelphia-negative chronic myeloproliferative syndrome treated with Phosphorus-32P in our hospital from January 1985 to March 2017&#46; Indications&#44; response to treatment&#44; as well as early and late complications have been analyzed&#46;</p></span> <span id="abst0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0020">Results</span><p id="spar0035" class="elsevierStyleSimplePara elsevierViewall">Of the 17 patients treated with 32P &#40;11 men&#44; 6 women&#59; mean age 79&#44;8 years&#41;&#44; 6 patients had Polycythemia Vera and 11 Essential Thrombocytosis&#46; A single dose was administered in 9 of the subjects&#44; the rest required two or more doses due to inadequate hematological response and&#47;or relapse&#46; The total dose range of Phosphorus-32P administered was 116&#8722;951&#8239;MBq &#40;median&#58; 236&#8239;MBq&#41;&#46; In 14 patients treated with Phosphorus-32P&#44; complete or partial response was achieved in hematimetry&#46; In 11 patients&#44; the response was complete&#44; established as a platelet count &#60;400&#46;000&#47;mm<span class="elsevierStyleSup">3</span> in those diagnosed with Essential Thrombocythemia and a hematocrit &#60;45&#37; in cases of Polycythemia Vera&#46; The median follow-up of patients from the date of the first treatment of Phosphorus-32P until study completion or death was 37 months &#40;range&#58; 5&#8211;230 months&#41;&#46; Regarding early complications&#44; 2 cases of anemia requiring blood transfusion were observed&#44; and 1 case of mild thrombocytopenia&#46; No leukemic transformation was identified&#46;</p></span> <span id="abst0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0025">Conclusions</span><p id="spar0040" class="elsevierStyleSimplePara elsevierViewall">In our experience&#44; treatment with Phosphorus-32P has been a useful therapeutic option in Philadelphia-negative chronic myeloproliferative syndromes in elderly patients who showed poor tolerance and&#47;or resistance to first-line treatment&#46; No leukemic transformation was identified&#46;</p></span>"
        "secciones" => array:4 [
          0 => array:2 [
            "identificador" => "abst0005"
            "titulo" => "Objective"
          ]
          1 => array:2 [
            "identificador" => "abst0010"
            "titulo" => "Material and methods"
          ]
          2 => array:2 [
            "identificador" => "abst0015"
            "titulo" => "Results"
          ]
          3 => array:2 [
            "identificador" => "abst0020"
            "titulo" => "Conclusions"
          ]
        ]
      ]
      "es" => array:3 [
        "titulo" => "Resumen"
        "resumen" => "<span id="abst0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0035">Objetivo</span><p id="spar0045" class="elsevierStyleSimplePara elsevierViewall">Describir nuestra experiencia en el tratamiento con F&#243;sforo-<span class="elsevierStyleSup">32</span>P de s&#237;ndromes mieloproliferativos cr&#243;nicos Philadelphia negativos refractarios o con efectos secundarios al tratamiento habitual&#59; con especial atenci&#243;n a sus complicaciones y al riesgo de transformaci&#243;n leuc&#233;mica&#46;</p></span> <span id="abst0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0040">Material y m&#233;todos</span><p id="spar0050" class="elsevierStyleSimplePara elsevierViewall">Estudio descriptivo retrospectivo incluyendo 17 pacientes con diagn&#243;stico de s&#237;ndrome mieloproliferativo cr&#243;nico Philadelphia negativo tratados con F&#243;sforo-<span class="elsevierStyleSup">32</span>P en nuestro hospital desde enero de 1985 a marzo de 2017&#46; Se han analizado las indicaciones&#44; la respuesta al tratamiento&#44; as&#237; como las complicaciones precoces y tard&#237;as&#46;</p></span> <span id="abst0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0045">Resultados</span><p id="spar0055" class="elsevierStyleSimplePara elsevierViewall">De los 17 pacientes tratados con <span class="elsevierStyleSup">32</span>P &#40;11 hombres&#44; 6 mujeres&#59; edad media 79&#44;8 a&#241;os&#41;&#44; 6 pacientes presentaban Policitemia Vera y 11 Trombocitosis Esencial&#46; En 9 de los sujetos se administr&#243; una &#250;nica dosis&#44; el resto requirieron dos o m&#225;s dosis por inadecuada respuesta hematol&#243;gica y&#47;o reca&#237;da&#46; El rango de dosis total de F&#243;sforo-<span class="elsevierStyleSup">32</span>P administrada fue de 116&#8722;951&#8239;MBq &#40;mediana&#58; 236&#8239;MBq&#41;&#46; En 14 pacientes tratados con F&#243;sforo-<span class="elsevierStyleSup">32</span>P se consigue respuesta completa o parcial en la hematimetr&#237;a&#46; En 11 pacientes la respuesta fue completa&#44; establecida como una cifra de plaquetas &#60;400&#46;000&#47;mm<span class="elsevierStyleSup">3</span> en aquellos diagnosticados de Trombocitemia Esencial y un hematocrito &#60;45&#37; en los casos de Policitemia Vera&#46; La mediana del seguimiento de los pacientes desde la fecha del primer tratamiento con F&#243;sforo-<span class="elsevierStyleSup">32</span>P hasta la finalizaci&#243;n del estudio o su fallecimiento fue de 37 meses &#40;rango&#58; 5&#8211;230 meses&#41;&#46; Respecto a las complicaciones precoces&#44; se objetivaron 2 casos de anemia que requirieron transfusi&#243;n sangu&#237;nea y 1 caso trombopenia de grado leve&#46; No se identific&#243; ninguna transformaci&#243;n leuc&#233;mica&#46;</p></span> <span id="abst0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0050">Conclusiones</span><p id="spar0060" class="elsevierStyleSimplePara elsevierViewall">En nuestra experiencia&#44; el tratamiento con F&#243;sforo-<span class="elsevierStyleSup">32</span>P ha sido una opci&#243;n terap&#233;utica &#250;til en los s&#237;ndromes mieloproliferativos cr&#243;nicos Philadelphia negativos en pacientes de edad avanzada que mostraban mala tolerancia y&#47;o resistencia al tratamiento de primera l&#237;nea&#46; No hemos identificado ning&#250;n caso de transformaci&#243;n leuc&#233;mica&#46;</p></span>"
        "secciones" => array:4 [
          0 => array:2 [
            "identificador" => "abst0025"
            "titulo" => "Objetivo"
          ]
          1 => array:2 [
            "identificador" => "abst0030"
            "titulo" => "Material y m&#233;todos"
          ]
          2 => array:2 [
            "identificador" => "abst0035"
            "titulo" => "Resultados"
          ]
          3 => array:2 [
            "identificador" => "abst0040"
            "titulo" => "Conclusiones"
          ]
        ]
      ]
    ]
    "multimedia" => array:4 [
      0 => array:8 [
        "identificador" => "fig0005"
        "etiqueta" => "Figure 1"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr1.jpeg"
            "Alto" => 1199
            "Ancho" => 1591
            "Tamanyo" => 93610
          ]
        ]
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at0005"
            "detalle" => "Figure "
            "rol" => "short"
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Tipo de respuesta a la primera dosis de <span class="elsevierStyleSup">32</span>P&#46;</p>"
        ]
      ]
      1 => array:8 [
        "identificador" => "fig0010"
        "etiqueta" => "Figure 2"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr2.jpeg"
            "Alto" => 1452
            "Ancho" => 1425
            "Tamanyo" => 113299
          ]
        ]
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at0010"
            "detalle" => "Figure "
            "rol" => "short"
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">Seguimiento y retratamiento con <span class="elsevierStyleSup">32</span>P&#46;</p>"
        ]
      ]
      2 => array:7 [
        "identificador" => "tbl0005"
        "etiqueta" => "Table 1"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at0015"
            "detalle" => "Table "
            "rol" => "short"
          ]
        ]
        "tabla" => array:2 [
          "leyenda" => "<p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">M&#58; male&#59; F&#58; fenale&#59; ET&#58;essential thrombocythemia&#59; PV&#58; polycythemia vera&#59; JAK2&#58; activating mutation of the JAK2 gene&#59; ND&#58; not done&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">N&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Sex&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Age&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Body surface&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Type of MPS mutation&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Mutaci&#243;n&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Comorbidity&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Treatment of MPS at referral&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Indication of <span class="elsevierStyleSup">32</span>P&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">M&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">83&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&#46;81&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">ET&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">JAK2 &#8722;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">YES&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Anagrelide&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Bad tolerance&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">M&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">84&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&#46;82&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">ET&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">ND&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">YES&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Hydroxyurea&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Inadequate control&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">M&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">84&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2&#46;33&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">PV&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">ND&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">YES&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Hydroxyurea&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Inadequate control and bad tolerance&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">4&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">M&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">79&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&#46;82&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">ET&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">ND&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">YES&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Hydroxyurea&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Inadequate control&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">5&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">M&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">85&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&#46;37&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">PV&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">JAK2 &#43;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">YES&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Phlebotomies&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Inadequate control&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">6&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">M&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">75&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&#46;9&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">ET&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">ND&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">YES&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Hydroxyurea&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Inadequate control&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">7&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">F&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">73&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&#46;49&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">ET&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">ND&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">YES&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Hydroxyurea and anagrelide&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Inadeqaute control&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">8&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">F&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">88&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&#46;43&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">ET&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">ND&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">YES&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Hydroxyurea&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Inadequate control and bad tolerance&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">9&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">F&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">87&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&#46;51&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">ET&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">ND&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">YES&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Hydroxyurea and anagrelide&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Inadequate control and bad tolerance&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">10&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">M&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">70&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&#46;82&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">PV&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">ND&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">YES&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Hydroxyurea&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Bad tolerance&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">11&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">F&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">66&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&#46;61&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">PV&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">ND&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">YES&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Bad tolerance&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">12&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">M&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">78&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&#46;4&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">PV&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">ND&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">YES&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Bad tolerance&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">13&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">F&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">82&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&#46;49&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">ET&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">JAK2 &#8722;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">YES&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Hydroxyurea&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Inadequate control&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">14&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">M&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">79&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&#46;87&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">ET&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">JAK2 &#43;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">YES&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Hydroxyurea&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Bad tolerance&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">15&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">F&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">80&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&#46;67&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">ET&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">JAK2 &#43;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">NO&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Bad tolerance&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">16&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">M&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">87&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2&#46;08&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">ET&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">JAK2 &#8722;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">YES&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Bad tolerance&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">17&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">M&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">77&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&#46;71&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">PV&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">JAK2 &#43;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">YES&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Phlebotomies&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Bad tolerance&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab3675203.png"
              ]
            ]
          ]
        ]
      ]
      3 => array:7 [
        "identificador" => "tbl0010"
        "etiqueta" => "Table 2"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at0020"
            "detalle" => "Table "
            "rol" => "short"
          ]
        ]
        "tabla" => array:2 [
          "leyenda" => "<p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">ET&#58; essential thrombocythemia&#59; PV&#58; polycythemia vera&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">N&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Type oF MPS&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Total dose of <span class="elsevierStyleSup">32</span>P MBq &#40;mCi&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Early complications&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Response TO 32P&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Late hematological complications&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Follow-up time &#40;months&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">ET&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">138 &#40;3&#46;7&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Complete response&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">9&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">ET&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">195 &#40;5&#46;2&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Partial response&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">75&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">PV&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">236 &#40;6&#46;3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Complete response&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">25&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">4&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">ET&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">185 &#40;5&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Partial response&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">31&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">5&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">PV&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">116 &#40;3&#46;1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Thrombopenia&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">No response&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">77&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">6&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">ET&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">199 &#40;5&#46;4&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Anemia&#44; required transfusion&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Complete response&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">W&#228;ldestrom disease&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">37&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">7&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">ET&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">360 &#40;9&#46;7&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Partial response&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">33&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">8&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">ET&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">338 &#40;9&#46;1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Complete response&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">37&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">9&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">ET&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">321 &#40;8&#46;6&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Anemia&#44; required transfusion&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">No response&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">29&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">10&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">PV&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">158 &#40;4&#46;2&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">No response&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">39&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">11&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">PV&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">410 &#40;11&#46;1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Complete response&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">90&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">12&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">PV&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">241 &#40;6&#46;5&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Complete response&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">230&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">13&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">ET&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">151 &#40;4&#46;1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Complete response&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">5&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">14&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">ET&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">370 &#40;10&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Complete response&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">31&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">15&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">ET&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">185 &#40;5&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Complete response&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">38&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">16&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">ET&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">951 &#40;25&#46;7&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Complete response&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">80&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">17&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">PV&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">370 &#40;10&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Complete response&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">21&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab3675202.png"
              ]
            ]
          ]
        ]
      ]
    ]
    "bibliografia" => array:2 [
      "titulo" => "References"
      "seccion" => array:1 [
        0 => array:2 [
          "identificador" => "bibs0005"
          "bibliografiaReferencia" => array:31 [
            0 => array:3 [
              "identificador" => "bib0005"
              "etiqueta" => "1"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "D&#46;A&#46; Arber"
                            1 => "A&#46; Orazi"
                            2 => "R&#46; Hasserjian"
                            3 => "J&#46; Thiele"
                            4 => "M&#46;J&#46; Borowitz"
                            5 => "M&#46;M&#46; Le Beau"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1182/blood-2016-03-643544"
                      "Revista" => array:7 [
                        "tituloSerie" => "Blood&#46;"
                        "fecha" => "2016"
                        "volumen" => "127"
                        "numero" => "20"
                        "paginaInicial" => "2391"
                        "paginaFinal" => "2405"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27069254"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            1 => array:3 [
              "identificador" => "bib0010"
              "etiqueta" => "2"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Philadelphia-negative classical myeloproliferative neoplasms&#59; critical concepts and management recommendations from European LeukemiaNet"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:4 [
                            0 => "T&#46; Barbui"
                            1 => "G&#46; Barosi"
                            2 => "G&#46; Birgegard"
                            3 => "F&#46; Cervantes"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1200/JCO.2010.31.8436"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Clin Oncol&#46;"
                        "fecha" => "2011"
                        "volumen" => "29"
                        "paginaInicial" => "761"
                        "paginaFinal" => "770"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21205761"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            2 => array:3 [
              "identificador" => "bib0015"
              "etiqueta" => "3"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Survival and prognosis among 1545 patients with contemporary polycythemia vera&#58; an international study"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "A&#46; Tefferi"
                            1 => "E&#46; Rumi"
                            2 => "G&#46; Finazzi"
                            3 => "H&#46; Gisslinger"
                            4 => "A&#46;M&#46; Vannucchi"
                            5 => "F&#46; Rodeghiero"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Leukemia&#46;"
                        "fecha" => "2013"
                        "volumen" => "27"
                        "numero" => "9"
                        "paginaInicial" => "1874"
                        "paginaFinal" => "1881"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            3 => array:3 [
              "identificador" => "bib0020"
              "etiqueta" => "4"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Epidemiological&#44; diagnostic&#44; therapeutic&#44; and prognostic aspects of essential thrombocythemia in a retrospective study of the GIMMC group in two thousand patients"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "L&#46; Gugliotta"
                            1 => "R&#46; Marchioli"
                            2 => "M&#46; Fiacchini"
                            3 => "N&#46; Vianelli"
                            4 => "S&#46; Baravelli"
                            5 => "L&#46; Valdr&#232;"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Blood&#46;"
                        "fecha" => "1997"
                        "volumen" => "90"
                        "numero" => "Suppl 1"
                        "paginaInicial" => "1551"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            4 => array:3 [
              "identificador" => "bib0025"
              "etiqueta" => "5"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Advances in understanding and management of myeloproliferative neoplasms"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "A&#46;M&#46; Vannucchi"
                            1 => "P&#46; Guglielmelli"
                            2 => "A&#46; Tefferi"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.3322/caac.20009"
                      "Revista" => array:7 [
                        "tituloSerie" => "CA Cancer J Clin&#46;"
                        "fecha" => "2009"
                        "volumen" => "59"
                        "numero" => "3"
                        "paginaInicial" => "171"
                        "paginaFinal" => "191"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19369682"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            5 => array:3 [
              "identificador" => "bib0030"
              "etiqueta" => "6"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Myeloproliferative neoplasm &#40;MPN&#41; symptom assessment form total symptom score&#58; prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "R&#46;M&#46; Emanuel"
                            1 => "A&#46;C&#46; Dueck"
                            2 => "H&#46;L&#46; Geyer"
                            3 => "J&#46;J&#46; Kiladjian"
                            4 => "S&#46; Slot"
                            5 => "S&#46; Zweegman"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "J Clin Oncol&#46;"
                        "fecha" => "2012"
                        "volumen" => "30"
                        "numero" => "33"
                        "paginaInicial" => "4098"
                        "paginaFinal" => "4103"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            6 => array:3 [
              "identificador" => "bib0035"
              "etiqueta" => "7"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Development and validation of an International Prognostic Score of thrombosis in World Health Organization&#8211;essential thrombocythemia &#40;IPSET-thrombosis&#41;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "T&#46; Barbui"
                            1 => "G&#46; Finazzi"
                            2 => "A&#46; Carobbio"
                            3 => "J&#46; Thiele"
                            4 => "F&#46; Passamonti"
                            5 => "E&#46; Rumi"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1182/blood-2012-07-444067"
                      "Revista" => array:7 [
                        "tituloSerie" => "Blood&#46;"
                        "fecha" => "2012"
                        "volumen" => "120"
                        "paginaInicial" => "5128"
                        "paginaFinal" => "5133"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23033268"
                            "web" => "Medline"
                          ]
                        ]
                        "itemHostRev" => array:3 [
                          "pii" => "S1058274614005205"
                          "estado" => "S300"
                          "issn" => "10582746"
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            7 => array:3 [
              "identificador" => "bib0040"
              "etiqueta" => "8"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "T&#46; Barbui"
                            1 => "A&#46;M&#46; Vannucchi"
                            2 => "V&#46; Buxhofer-Ausch"
                            3 => "V&#46; De Stefano"
                            4 => "S&#46; Betti"
                            5 => "A&#46; Rambaldi"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1038/bcj.2015.94"
                      "Revista" => array:6 [
                        "tituloSerie" => "Blood Cancer J&#46;"
                        "fecha" => "2015"
                        "volumen" => "5"
                        "numero" => "11"
                        "paginaInicial" => "e369"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26617062"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            8 => array:3 [
              "identificador" => "bib0045"
              "etiqueta" => "9"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Nuclear physics and therapy&#58; preliminary report of a new method for the treatment of leukemia and polycythemia"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:1 [
                            0 => "J&#46;H&#46; Lawrence"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Radiology&#46;"
                        "fecha" => "1940"
                        "volumen" => "52"
                        "paginaInicial" => "51"
                        "paginaFinal" => "60"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            9 => array:3 [
              "identificador" => "bib0050"
              "etiqueta" => "10"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Polycythemia vera&#58; historical oversights&#44; diagnostic details&#44; and therapeutic views"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "A&#46; Tefferi"
                            1 => "A&#46;M&#46; Vannucchi"
                            2 => "T&#46; Barbui"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1038/s41375-021-01401-3"
                      "Revista" => array:6 [
                        "tituloSerie" => "Leukemia&#46;"
                        "fecha" => "2021"
                        "volumen" => "35"
                        "paginaInicial" => "3339"
                        "paginaFinal" => "3351"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/34480106"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            10 => array:3 [
              "identificador" => "bib0055"
              "etiqueta" => "11"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Developments in diagnosis and treatment of essential thrombocythemia"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "B&#46; Mora"
                            1 => "F&#46; Passamonti"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1080/17474086.2019.1585239"
                      "Revista" => array:7 [
                        "tituloSerie" => "Expert Rev Hematol&#46;"
                        "fecha" => "2019"
                        "volumen" => "12"
                        "numero" => "3"
                        "paginaInicial" => "159"
                        "paginaFinal" => "171"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/30793984"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            11 => array:3 [
              "identificador" => "bib0060"
              "etiqueta" => "12"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Revised Response Criteria for polycythemia vera and essential thrombocythemia&#58; an ELN and IWG-MRT consensus project"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:5 [
                            0 => "G&#46; Barosi"
                            1 => "R&#46; Mesa"
                            2 => "G&#46; Finazzi"
                            3 => "C&#46; Harrison"
                            4 => "J&#46; Kiladjian"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1182/blood-2013-01-478891"
                      "Revista" => array:6 [
                        "tituloSerie" => "Blood&#46;"
                        "fecha" => "2013"
                        "volumen" => "121"
                        "paginaInicial" => "4778"
                        "paginaFinal" => "4781"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23591792"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            12 => array:3 [
              "identificador" => "bib0065"
              "etiqueta" => "13"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "EANM procedure guideline for 32P phosphate treatment of myeloproliferative diseases"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "J&#46; Tennvall"
                            1 => "B&#46; Brans"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1007/s00259-007-0407-4"
                      "Revista" => array:7 [
                        "tituloSerie" => "Eur J Nucl Med Mol Imaging&#46;"
                        "fecha" => "2007"
                        "volumen" => "34"
                        "paginaInicial" => "1324"
                        "paginaFinal" => "1327"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17396258"
                            "web" => "Medline"
                          ]
                        ]
                        "itemHostRev" => array:3 [
                          "pii" => "S2468602619301718"
                          "estado" => "S300"
                          "issn" => "26666383"
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            13 => array:3 [
              "identificador" => "bib0070"
              "etiqueta" => "14"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Treatment of the myeloproliferative disorders with P-32"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:1 [
                            0 => "N&#46;I&#46; Berlin"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1034/j.1600-0609.2000.9r119.x"
                      "Revista" => array:6 [
                        "tituloSerie" => "Eur J Haematol&#46;"
                        "fecha" => "2000"
                        "volumen" => "65"
                        "paginaInicial" => "1"
                        "paginaFinal" => "7"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/10914933"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            14 => array:3 [
              "identificador" => "bib0075"
              "etiqueta" => "15"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Haematological complications in polycythaemia vera and thrombocythaemia patients treated with radiophosphorus &#40;32P&#41;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:4 [
                            0 => "M&#46; Randi"
                            1 => "F&#46; Fabris"
                            2 => "L&#46; Varotto"
                            3 => "C&#46; Rossi"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Folia Haematol Int Mag Klin Morphol Blutforsch&#46;"
                        "fecha" => "1990"
                        "volumen" => "117"
                        "paginaInicial" => "461"
                        "paginaFinal" => "467"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/1703118"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            15 => array:3 [
              "identificador" => "bib0080"
              "etiqueta" => "16"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Blast transformation in myeloproliferative neoplasms&#58; risk factors&#44; biological findings&#44; and targeted therapeutic options"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "A&#46; Iurlo"
                            1 => "D&#46; Cattaneo"
                            2 => "U&#46; Gianelli"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.3390/ijms20081839"
                      "Revista" => array:5 [
                        "tituloSerie" => "Int J Mol Sci&#46;"
                        "fecha" => "2019"
                        "volumen" => "20"
                        "paginaInicial" => "1839"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31013941"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            16 => array:3 [
              "identificador" => "bib0085"
              "etiqueta" => "17"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Acute leukemia in polycythemia vera&#58; An analysis of 1638 patients enrolled in a prospective observational study"
                      "autores" => array:1 [
                        0 => array:3 [
                          "colaboracion" => "ECLAP Investigators"
                          "etal" => true
                          "autores" => array:6 [
                            0 => "G&#46; Finazzi"
                            1 => "V&#46; Caruso"
                            2 => "R&#46; Marchioli"
                            3 => "G&#46; Capnist"
                            4 => "T&#46; Chisesi"
                            5 => "C&#46; Finelli"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1182/blood-2004-09-3426"
                      "Revista" => array:6 [
                        "tituloSerie" => "Blood"
                        "fecha" => "2005"
                        "volumen" => "105"
                        "paginaInicial" => "2664"
                        "paginaFinal" => "2670"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15585653"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            17 => array:3 [
              "identificador" => "bib0090"
              "etiqueta" => "18"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "The natural history and treatment outcome of blast phase BCR-ABL- myeloproliferative neoplasms"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "C&#46;S&#46; Tam"
                            1 => "R&#46;M&#46; Nussenzveig"
                            2 => "U&#46; Popat"
                            3 => "C&#46;E&#46; Bueso-Ramos"
                            4 => "D&#46;A&#46; Thomas"
                            5 => "J&#46;A&#46; Cortes"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Blood&#46;"
                        "fecha" => "2008"
                        "volumen" => "112"
                        "paginaInicial" => "1628"
                        "paginaFinal" => "1637"
                        "itemHostRev" => array:3 [
                          "pii" => "S0749806313011213"
                          "estado" => "S300"
                          "issn" => "07498063"
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            18 => array:3 [
              "identificador" => "bib0095"
              "etiqueta" => "19"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "AML transformation in 56 patients with Ph- MPD in two well defined populations"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "K&#46; Abdulkarim"
                            1 => "F&#46; Girodon"
                            2 => "P&#46; Johansson"
                            3 => "M&#46; Maynadi&#233;"
                            4 => "J&#46; Kutti"
                            5 => "P&#46;M&#46; Carli"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/j.1600-0609.2008.01163.x"
                      "Revista" => array:7 [
                        "tituloSerie" => "Eur&#46; J&#46; Haematol&#46;"
                        "fecha" => "2009"
                        "volumen" => "82"
                        "paginaInicial" => "106"
                        "paginaFinal" => "111"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19134023"
                            "web" => "Medline"
                          ]
                        ]
                        "itemHostRev" => array:3 [
                          "pii" => "S1058274614001840"
                          "estado" => "S300"
                          "issn" => "10582746"
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            19 => array:3 [
              "identificador" => "bib0100"
              "etiqueta" => "20"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "3023 Mayo Clinic patients with myeloproliferative neoplasms&#58; risk-stratified comparison of survival and outcomes data among disease subgroups"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [
                            0 => "N&#46; Szuber"
                            1 => "M&#46; Mudireddy"
                            2 => "M&#46; Nicolosi"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.mayocp.2018.08.022"
                      "Revista" => array:6 [
                        "tituloSerie" => "Mayo Clin Proc&#46;"
                        "fecha" => "2019"
                        "volumen" => "94"
                        "paginaInicial" => "599"
                        "paginaFinal" => "610"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/30824279"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            20 => array:3 [
              "identificador" => "bib0105"
              "etiqueta" => "21"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Acute myeloid leukemia following myeloproliferative neoplasms&#58; a review of what we know&#44; what we do not know&#44; and emerging treatment strategies"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "Z&#46; McKinnell"
                            1 => "D&#46; Karel"
                            2 => "D&#46; Tuerff"
                            3 => "M&#46; Sh Abrahim"
                            4 => "S&#46; Nassereddine"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.14740/jh1042"
                      "Revista" => array:7 [
                        "tituloSerie" => "J Hematol&#46;"
                        "fecha" => "2022"
                        "volumen" => "11"
                        "numero" => "6"
                        "paginaInicial" => "197"
                        "paginaFinal" => "209"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/36632576"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            21 => array:3 [
              "identificador" => "bib0110"
              "etiqueta" => "22"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Blast phase myeloproliferative neoplasm&#58; Mayo-AGIMM study of 410 patients from two separate cohorts"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [
                            0 => "A&#46; Tefferi"
                            1 => "M&#46; Mudireddy"
                            2 => "F&#46; Mannelli"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1038/s41375-018-0019-y"
                      "Revista" => array:6 [
                        "tituloSerie" => "Leukemia&#46;"
                        "fecha" => "2018"
                        "volumen" => "32"
                        "paginaInicial" => "1200"
                        "paginaFinal" => "1210"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29459662"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            22 => array:3 [
              "identificador" => "bib0115"
              "etiqueta" => "23"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Leukemia secondary to myeloproliferative neoplasm"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "A&#46;J&#46; Dunvar"
                            1 => "R&#46;K&#46; Rampal"
                            2 => "R&#46; Levine"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1182/blood.2019000943"
                      "Revista" => array:7 [
                        "tituloSerie" => "Blood&#46;"
                        "fecha" => "2020"
                        "volumen" => "136"
                        "numero" => "1"
                        "paginaInicial" => "61"
                        "paginaFinal" => "70"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32430500"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            23 => array:3 [
              "identificador" => "bib0120"
              "etiqueta" => "24"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Guidelines for the diagnosis&#44; investigation and management of polycythemia&#47;erythrocytosis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:2 [
                            0 => "M&#46; McMullin"
                            1 => "D&#46; Bareford"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Brit J Haematol&#46;"
                        "fecha" => "2005"
                        "volumen" => "130"
                        "paginaInicial" => "174"
                        "paginaFinal" => "195"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            24 => array:3 [
              "identificador" => "bib0125"
              "etiqueta" => "25"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Treatment of polycythemia vera&#58; use of 32P alone or in combination withmaintenance therapy using hydroxyurea in 461 patients greater than 65 years of age&#46; The French Polycythemia Study Group"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "Y&#46; Najean"
                            1 => "J&#46;D&#46; Rain"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:7 [
                        "tituloSerie" => "Blood"
                        "fecha" => "1997"
                        "volumen" => "89"
                        "paginaInicial" => "2319"
                        "paginaFinal" => "2327"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/9116275"
                            "web" => "Medline"
                          ]
                        ]
                        "itemHostRev" => array:3 [
                          "pii" => "S0749806322002237"
                          "estado" => "S300"
                          "issn" => "07498063"
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            25 => array:3 [
              "identificador" => "bib0130"
              "etiqueta" => "26"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Survival and risk of leukemia in polycythemia vera and essential thrombocythemia treated with oral radiophosphorus"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "L&#46; Brandt"
                            1 => "H&#46; Anderson"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/j.1600-0609.1995.tb01621.x"
                      "Revista" => array:6 [
                        "tituloSerie" => "Eur J Haematol&#46;"
                        "fecha" => "1995"
                        "volumen" => "54"
                        "paginaInicial" => "21"
                        "paginaFinal" => "26"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/7859872"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            26 => array:3 [
              "identificador" => "bib0135"
              "etiqueta" => "27"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Outcome of 259 patients with primary proliferative polycythaemia &#40;PPP&#41; and idiopathic thrombocythaemia &#40;IT&#41; treated in a regional nuclear medicine department with phosphorus-32--a 15 year review"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "K&#46;K&#46; Balan"
                            1 => "M&#46; Critchley"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1259/bjr.70.839.9536909"
                      "Revista" => array:6 [
                        "tituloSerie" => "Brit J Radiol&#46;"
                        "fecha" => "1997"
                        "volumen" => "70"
                        "paginaInicial" => "1169"
                        "paginaFinal" => "1173"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/9536909"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            27 => array:3 [
              "identificador" => "bib0140"
              "etiqueta" => "28"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Myeloid blastic transformation of myeloproliferative neoplasms- a review of 112 cases"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "S&#46;J&#46; Noor"
                            1 => "W&#46; Tan"
                            2 => "G&#46;E&#46; Wildingb"
                            3 => "A&#46; Laurie"
                            4 => "L&#46;A&#46; Ford"
                            5 => "M&#46; Barcos"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Leuk Res&#46;"
                        "fecha" => "2011"
                        "volumen" => "35"
                        "paginaInicial" => "608"
                        "paginaFinal" => "613"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            28 => array:3 [
              "identificador" => "bib0145"
              "etiqueta" => "29"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Treatment-related risk factors for transformation to acute myeloid leukemia and myelodisplastic syndromes in myeloproliferative neoplasms"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:2 [
                            0 => "M&#46; Bjorkhokm"
                            1 => "R&#46; &#197;sa"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1200/JCO.2011.34.7542"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Clin Oncol&#46;"
                        "fecha" => "2011"
                        "volumen" => "29"
                        "paginaInicial" => "2410"
                        "paginaFinal" => "2415"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21537037"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            29 => array:3 [
              "identificador" => "bib0150"
              "etiqueta" => "30"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "32P in the treatment of myeloproliferative disorders"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "S&#46; Lawless"
                            1 => "M&#46;F&#46; McMullin"
                            2 => "R&#46; Cuthbert"
                            3 => "R&#46; Houston"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:8 [
                        "tituloSerie" => "Ulster Med J&#46;"
                        "fecha" => "2016"
                        "volumen" => "85"
                        "numero" => "2"
                        "paginaInicial" => "83"
                        "paginaFinal" => "85"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27601760"
                            "web" => "Medline"
                          ]
                        ]
                        "itemHostRev" => array:3 [
                          "pii" => "S1058274615002840"
                          "estado" => "S300"
                          "issn" => "10582746"
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            30 => array:3 [
              "identificador" => "bib0155"
              "etiqueta" => "31"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Combined chemotherapy and endoscopic ultrasound-guided intratumoral 32P implantation for locally advanced pancreatic adenocarcinoma&#58; a pilot study"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [
                            0 => "J&#46; Naidu"
                            1 => "D&#46; Bartholomeusz"
                            2 => "J&#46; Zobel"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:7 [
                        "tituloSerie" => "Endoscopy&#46;"
                        "fecha" => "2022"
                        "volumen" => "54"
                        "numero" => "1"
                        "paginaInicial" => "75"
                        "paginaFinal" => "80"
                        "itemHostRev" => array:3 [
                          "pii" => "S0749806320307271"
                          "estado" => "S300"
                          "issn" => "07498063"
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
          ]
        ]
      ]
    ]
  ]
  "idiomaDefecto" => "en"
  "url" => "/22538089/unassign/S2253808924000922/v1_202410020434/en/main.assets"
  "Apartado" => null
  "PDF" => "https://static.elsevier.es/multimedia/22538089/unassign/S2253808924000922/v1_202410020434/en/main.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2253808924000922?idApp=UINPBA00004N"
]
Article information
ISSN: 22538089
Original language: English
DOI:10.1016/j.remnie.2024.500064
The statistics are updated each day

Follow this link to access the full text of the article

Subscribe to our newsletter

Publish in
Revista Española de Medicina Nuclear e Imagen Molecular
Revista Española de Medicina Nuclear e Imagen Molecular (English Edition) is a member and subscribes the principles of, the Committee on Publication Ethics (COPE)
www.publicationethics.org.
Free access articles
Imaging of desmoplastic small round-cell tumor on
Rev Esp Med Nucl Imagen Mol. 2024;43:
Assessment of incidental cardiac uptake in bone...
Rev Esp Med Nucl Imagen Mol. 2024;43:
Diagnostic performance of a novel deep learning attenuation...
Rev Esp Med Nucl Imagen Mol. 2024;43:23-30
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos